Stock 688177 BIO-THERA SOLUTIONS, LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Bio-Thera Solutions, Ltd.

Equities

688177

CNE100003R98

End-of-day quote Shanghai S.E.
Other stock markets
 03:30:00 06/05/2024 am IST 		5-day change 1st Jan Change
34.18 CNY +3.20% Intraday chart for Bio-Thera Solutions, Ltd. +6.65% -17.12%
29/04 Bio-Thera Solutions, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
25/03 Bio-Thera Solutions Receives IND Clearance From US FDA to Initiate a Phase II Study for BAT8006 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Bio-Thera Solutions, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Bio-Thera Solutions Receives IND Clearance from US FDA to Initiate a Phase II Study for BAT8006, an Innovative Antibody Drug Conjugate Targeting Folate Receptor
AQ
Bio-Thera Solutions Receives IND Clearance From US FDA to Initiate a Phase II Study for BAT8006
CI
Bio-Thera Solutions Grants Marketing Rights of Two Drugs to Latin American Company
MT
Bio-Thera Solutions, Ltd. Partners with SteinCares to Market Two Biosimilars in LATAM
CI
Bio-Thera Solutions, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Bio-Thera Solutions Announces Initiation of Phase IB / IIA Clinical Trial for BAT6026
CI
Bio-Thera Solutions Gets Regulatory Nod for Trial of Tumor Drug Combination Treatment
MT
Recent Biosimilar Approvals
AQ
Bio-Thera Solutions Wins US FDA Nod to Market Cancer Drug
MT
FDA Approves Bio-Thera Solutions' Avzivi (Bevacizumab-Tnjn), A Biosimilar Referencing Avastin
CI
Bio-Thera Solutions Announces Positive Results from Phase 3 Study of BAT2206, a Proposed Biosimilar Referencing Stelara
CI
Bio-Thera Solutions, Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Chugai Pharmaceutical Co., Ltd. - Notice of the Settlement of Patent Infringement Litigation in the U.S
AQ
Chugai Parent Roche Settles US Lawsuit Against Biogen Over Alleged Biosimilar Infringement
MT
Roche, Biogen Settle US Patent Infringement Case Over Actemra Biosimilar
MT
Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug
RE
Bio-Thera Partner Gets US FDA Marketing Nod for Arthritis Injectable
MT
FDA Approves Bio-Thera Solutions, Ltd.'s Partner Biogen Receives Notification from the United States Food and Drug Administration
CI
Biogen Says US FDA Approves Tocilizumab Biosimilar Tofidence
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 688177 Stock
  4. News Bio-Thera Solutions, Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW